Why TRAIL as a Therapy for Cancer has not been effective in Clinical Trials – NCI Center for Cancer Research
NCI Center for Cancer Research shared an article on LinkedIn:
“Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential cancer therapeutic that induces apoptosis in cancer cells while sparing non-malignant cells in preclinical models. However, its efficacy in clinical trials has been limited for unknown reasons.
In a recent CCR study, research led by Stanley Lipkowitz, produced data that may help explain why TRAIL as a therapy for cancer has not been effective in clinical trials. The team studied triple-negative breast cancer cells and discovered direct effects of TRAIL on the innate immune system that may compromise TRAIL’s antitumor activity. Their findings provide information that could help improve the treatment for use in the future.
Read more.
Video: The researchers used intravital imaging to show dendra-2-labeled MDA-MB-231 tumor cells (green) with and without TRAIL injection. The video on the left is 24 hours post-injection and shows increased recruitment of neutrophils (orange/yellow) compared to the untreated tumor on the right.”
TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells.
Authors: Manjari Kundu, Yoshimi E. Greer, Alexei Lobanov, Lisa Ridnour, Renee N. Donahue, Yeap Ng, Shashi Ratnayake, Karley White, Donna Voeller, Sarah Weltz, Qingrong Chen, Stephen J. Lockett, Maggie Cam, Daoud Meerzaman, David A. Wink, Roberto Weigert, Stanley Lipkowitz.
You can Read the Full Article on Journal of National Library of Medicine.
More posts featuring NCI Center for Cancer Research.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023